Fig. 3: PFS per subgroups. | Bone Marrow Transplantation

Fig. 3: PFS per subgroups.

From: Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT

Fig. 3: PFS per subgroups.

PFS - subgroup analyses according to time between transplants (a), achievement of VGPR or CR before the 2. ASCT (b), cytogenetic risk (c) and age at transplant (d). Shaded areas represent the 95% confidence interval and the p-values correspond to the results of the mdir log-rank test.

Back to article page